Ailing Qin
Tianjin Medical University Cancer Institute and Hospital · 19 works · 501 citations · h-index 9
Top works
- Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
- 92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
- 1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
- 289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies
- A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors
- LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
- EAT‐Lancet Diet Pattern, Genetic Predisposition, Inflammatory Biomarkers, and Risk of Lung Cancer Incidence and Mortality
- 510 POSTER Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours
- Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study
- A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti–platelet-derived growth factor &agr; (pdgfr&agr;) monoclonal antibody, in advanced soft tissue sarcoma (sts)
- Integrated analysis of microbiota and gut microbial metabolites in blood for breast cancer
- Association Between Volume, Intensity and Rhythm of Physical Activity Measured by Accelerometer and Risk of All‐Cause and Cause‐Specific Mortality in Individuals With MASLD
- PI-13Pharmacokinetics and pharmacodynamics of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors
- Sex disparity in the association between metabolic-anthropometric phenotypes and risk of obesity-related cancer: a prospective cohort study
- 472 A phase I study of IMGN388, an antibody drug conjugate targeting av integrin, in patients with solid tumors
- 1574P Trastuzumab deruxtecan versus ramucirumab and paclitaxel as second-line therapy for patients with her2-positive gastric or gastro-esophageal junction adenocarcinoma: A propensity score matched comparison
- P-184 A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
- Abstract 2346: Association of serum creatinine- and cystatin c-based diagnostic indices for sarcopenia with major chronic diseases
- Abstract 5040: Dietary advanced glycation end-products and risks of lung cancer and chronic respiratory diseases